• Industry article notes that successful direct-selling companies embrace smart systems that unify necessary tools to drive distributors’ success
• SHRG’s Elepreneurs adopting the interactive, video-based VERB sales-marketing app
• Elevacity D.O.S.E. products designed, formulated around scientifically backed, carefully researched ingredients

Integrating operations and activities into a single platform and fighting health problems through research and education are two key trends for the direct-selling sector moving into a new year, according to a recent article (http://ibn.fm/XZYuc), titled ‘The Top 7 Direct-Selling Trends to Watch for in 2020’. Sharing Services Global Corporation (OTCQB: SHRG), a diversified holdings company in the direct-selling industry, is leading out in these areas, as well as others designed to continue the company’s incredible momentum created in 2019.

“Since the majority of distributors are involved in a direct selling business only part-time and try to fit their side gig into busy schedules, every aspect of their entrepreneurial journey should be as smooth and easy as possible,” the article noted. “That’s why for direct-selling companies, it’s crucial to provide their distributors with tools and resources to ensure they have everything for easily achievable success. . . . Scattered solutions for every small challenge are not an option anymore. Successful direct-selling companies embrace smart systems that unify all the necessary tools to drive distributors’ success. Such systems are customizable to the core and combine training, engagement, genealogy management, payment processing, business development and other tools, ensuring that all the distributors are supported at each step on their way to success.”

On top of the trend, Sharing Services and its growing independent sales force, called Elepreneurs, use the interactive, video-based VERB sales-marketing app platform developed by Verb Technology Company Inc. (http://ibn.fm/lN51c). The innovative app combines world-class sales tools and allows users to track analytics in real time, deliver video messages, facilitate promotions and increase retention, manage social campaigns and much more. VERB is only the latest component of SHRG’s powerful selling strategy, which combines online technological tools and a specialized, seamless selling experience offered by its Elepreneurs.

SHRG’s implementation of VERB isn’t the only leading-edge move the company has made. The company created a wholly owned subsidiary – Elevacity LLC – that is focused on elevating health, wealth and happiness through a patented, powerful product line. Elevacity D.O.S.E. products are designed and formulated around scientifically backed, carefully researched ingredients proven to stimulate the happiness hormones: dopamine, oxytocin, serotonin and endorphins.

In addition to Elevacity, Sharing Services created a second subsidiary – named Elepreneurs LLC after its sales reps – specifically to answer the call of a new era of individuals in the gig economy who are looking for greater flexibility with income opportunities and a path to living happier, healthier and wealthier lives. Elepreneurs meets the needs of a “new era of social media and a widened consumer base that crosses industries and borders. ‘Relationship Marketing,’ or ‘word-of-mouth’ marketing breaks the traditional mold and creates competitiveness and big opportunities in the hands of small businesses across the company’s platform,” the company noted in a news release (http://ibn.fm/J4AQQ). “The company’s successful strategy reaches today’s market and consumers in an extremely cost-effective and more personal and direct approach.”

Since the creation of both Elepreneurs and Elevacity, along with the release of the D.O.S.E. products, Sharing Services has seen consistently impressive growth each quarter. “For the full fiscal year ended April 30, 2019, cash provided by operations was $6.0 million on annual sales of $85.9 million,” the company recently reported (http://ibn.fm/ZQrS9). “In addition, for the six months ended October 31, 2019, cash provided by operations was $12.1 million on sales of $74.3 million, while operating earnings were $3.9 million. As of October 31, 2019, cash and cash equivalents were $12.8 million.”

Sharing Services is dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies in the direct-selling industry. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors. Two of its primary divisions include Elevacity Holdings LLC (a product-sourcing and supply company) and Elepreneurs Holdings LLC (a sales and marketing company based on utilization of independent contractors as the sales force).

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Wonderfilm expects to generate $100 million in revenue by 2021, $20 million in deferred revenue early next year
• Company is backed by four Hollywood producers who produced over $1 billion dollars of hit movie revenue
• 69% of U.S. households now subscribe to streaming video services, up from 55% in 2017
• Entertainment and media industry’s revenue to reach $2.4 trillion globally in 2022

Wonderfilm Media Corporation (TSX.V: WNDR) (OTCQB: WDRFF), a leading entertainment company, is finding a lucrative market niche amid rising demand for streaming services. The race to capture content streaming consumers is a salient feature of entertainment, and the company has become more attractive to investors than ever before as a new provider of quality content.

Global demand for streaming content is at an unprecedented high. Almost a fifth of respondents in a survey by Colling Media stated they had canceled cable television, and 39% of consumers subscribed to streaming services between June and July 2019 (http://ibn.fm/Nxvac). Roughly 69% of U.S. households now subscribe to streaming video services, up from 55% in 2017. Consumers are willing to spend more on content they want, which is an excellent opportunity for companies like Wonderfilm.

Moreover, total global spending on entertainment and media is expected to rise at a compound annual growth rate (CAGR) of 4.4% over the next five years. The industry’s global revenue will reach $2.4 trillion in 2022 as a result, up from $1.9 trillion in 2017, a PwC report shows (http://ibn.fm/qb0Qk).

As streaming video on demand providers are investing in existing and new content heavily and making efforts to attract major filmmakers, Wonderfilm has an excellent opportunity to jump the bandwagon with around 100 films streaming on Netflix platform. The company differentiates itself by setting up each film as a single-purpose entity packaged for upfront sale, thereby eliminating filmmaking risk (http://ibn.fm/hqSw3).

Wonderfilm’s joint venture Wonderfilm Global, an international company distributing and selling film and TV, is expected to generate substantial revenue as well. The company had relationships with foreign buyers before launching the joint venture and being able to sell to them directly was an important milestone.

The company has lucrative prospects for many reasons. Giants like Google, Disney, Apple and Microsoft are competing with Netflix for streaming service subscribers. Wonderfilm caters to great demand for quality content and retains a continuing annual production slate of $58 million to meet the constant and growing need for content worldwide.

The company has eight green-lit in-development features representing $60 million in production budgets. These include Amityville 1974, in theatres October 2020, and the action film Inside Game with Tyrese Gibson, in theatres sometime in the fall of 2020. The company is also currently developing secured valuable IP rights.

Wonderfilm is backed by four Hollywood producers, who have over $1 billion worth of hit movie revenues under their belts. The company brings several leading industry executives with impressive track records of individual success into a new wider business model. Based on this model, they are capable of quickly financing and flexibly producing fresh slates of film and TV content for U.S. and foreign markets.

Wonderfilm expects $20 million in deferred revenue early this year and has positioned itself to realize $100 million in revenue by 2021. On the stock market, it is undervalued by a factor of 23 with a market cap of $5.2 million. It is a leading publicly traded entertainment company with offices in Los Angeles and Vancouver.

For more information, visit the company’s website at www.Wonderfilm.com

NOTE TO INVESTORS: The latest news and updates relating to WDRFF are available in the company’s newsroom at http://ibn.fm/WDRFF

• MCTC Holdings Inc. (soon to become Cannabis Global Inc.) is a cannabis science innovator working to develop marketable infusion technologies based on the premise of cannabinoid extract efficiency at extremely low quantities
• MCTC recently announced the launch of Project Varin, an effort to develop nanoparticle and nano fiber expressions of ultra-rare tetrahydrocannabivarin (THC-V) and to make those useful biologically at such extremely small levels
• The company also plans to develop the rare cannabinol (CBN) extract by the same means
• MCTC recently announced a new revenue stream through an infused coffee product under its Hemp You Can Feel label

Visionary cannabinoid science innovator MCTC Holdings Inc. (OTC: MCTC) is announcing a strategic effort to develop an efficient nanoparticle-based means of using the rare but potentially serviceable tetrahydrocannabivarin (THC-V) extract for purposes such as appetite suppression and obesity reduction.

Since reorganizing its management last year to focus its budding cannabis industry strategy on the science of alcohol replacement, MCTC Holdings has indicated its intentions to patent delivery methods that use minuscule particles of cannabis for a low-quantity but high-efficiency series of products. To that end, the company’s research and development strategy has included plans to delve into the potential of cannabis-based polymeric solid nanoparticles and nanofibers.

The company’s recent announcement states that it has launched Project Varin with the primary goal of developing THC-V delivery methods that significantly improve its bioavailability, using MCTC’s patent-pending technologies to produce THC-V polymeric nanoparticles and nanofibers (http://ibn.fm/WU5EA).

“THC-V is so rare and difficult to obtain, it is currently valued at around $500,000 per kilogram, which is approximately ten times the price of gold,” CEO Arman Tabatabaei stated in the news release. “In order for the marketplace to utilize this potentially beneficial exotic cannabinoid, new delivery systems will need to be developed to allow the amount of THC-V administered to be efficiently utilized by the human body… It is our goal to solve this pressing industry issue. Based on our already completed laboratory accomplishments and our patent-pending technologies, we believe this goal is within our reach.”

Nanoparticles have long been used by the food and medical industries to make products more efficient, turning extremely small substances into a means of quickly delivering their payloads directly to the bloodstream rather than following the dilutive and dilatory digestive tract mechanism commonly employed for swallowed products.

MCTC has been working toward an infused beverage product as a replacement for alcohol, and recently announced that it has developed a cannabinoid-infused clean label coffee that will be rolled out later this month under the company’s Hemp You Can Feel™ brand (http://ibn.fm/SuhJJ). MCTC plans to use its efficiency-promoting patents to harvest the benefits of cannabinoid extracts from very small amounts of the extract while achieving results that are similar or superior to other infusion methods, and to license its technology to other companies on a white label basis.

Under the first stage of development for THC-V, Project Varin is developing nanoparticle and nanofiber expressions of the extract using MCTC’s technology. In March, the second phase of development is expected to begin as the company applies its ongoing cannabinoid glycosides research to making THC-V useful at minimal usage levels.

“Interest in THC-V and Cannabinol (CBN) is quickly growing within the cannabinoid industry, and we believe both will be important topics throughout 2020 and beyond,” Tabatabaei stated. “With the recent availability of nearly 100% pure research quantities of these exotic cannabinoids now hitting the marketplace and the piquing interest, we believe our timing in launching Project Varin is optimal. … We plan to apply what we have learned and our new patent-pending technologies to THC-V and eventually to CBN.”

MCTC has filed five patents on hemp extract technologies and delivery systems.

For more information, visit the company’s website at www.CannabisGlobalInc.com

NOTE TO INVESTORS: The latest news and updates relating to MCTC are available in the company’s newsroom at http://ibn.fm/MCTC

• CIIX CEO said company will employ social media as it markets new CBD products starting March 2020
• CIIX subsidiary CBD Biotech Co. focused on driving growth, building online sales to younger demographics in China
• Goals of CIIX strategy include profitability, expansion of market, maximized impact

ChineseInvestors.com Inc. (OTCQB: CIIX) CEO Warren Wang said the company will adopt social media multiplatform techniques to market new CBD products beginning in March 2020. The move is designed to boost online sales to a younger demographic in China through its subsidiary CBD Biotech, explained Wang during a MoneyTV interview with host Donald Baillargeon. In the interview, Wang also outlined the company’s path to profitability in fiscal 2020 and 2021.

“CBD Biotech’s goal in 2020 is to make a profit,” Wang stated in the interview. “That is the key of the stock market. That’s the key for our stock price. That’s the key for our shareholders. CIIX plans to launch a breakthrough CBD product in March. It will debut through its B2B partners through social media, such as TikTok, and target in China a lot of young people.”

One important aspect of the company’s strategy to increase profit is to sell its new CBD product through e-commerce using different social media platforms in 2020. Wang observed that multi-platform social media would play a key role in the company’s marketing to a younger consumer audience of its CBD line. He specifically mentioned using platforms such as TikTok in the campaign, which launched in 2017 and accrued 500 million users in its first two years. Recently hailed as a “must for every small business,” social media marketing gives companies more direct access to their customers, meeting them where they are in a cost-effective way. Social media marketing has also been linked with increased brand recognition (http://ibn.fm/YOANZ), allowing companies to “target and retarget ideal consumers.” CIIX hopes to engage audiences of all ages through social media as it increases traction for its new CBD offerings.

In addition to its anticipated CBD product, CBD Biotech currently markets a line of hemp-infused cosmetics products in China. Wang estimates that cosmetics could deliver profit margins of 10-20 times for the company (http://ibn.fm/G89BP). “That’s quite a big profit,” he noted.

Referencing the high gross margins of CBD cosmetics, Wang said the company is working to bring more of that profitability down to the bottom line through lower costs and a restructuring. Wang explained that CIIX intends to expand its market as it maximizes sales through a split configuration of its B2B and B2C divisions.

The B2C division would focus on marketing and selling to consumers while the B2B division would be responsible for maximizing revenue to wholesalers and through multilevel social media outlets, he explained. The combined aim of the two divisions is to raise sales, cut costs and achieve profitability, he said.

Wang sees subsidiary CBD Biotech company reaching profitability by Q4 2020 fiscal year and continuing into 2021. “I am very positive about CBD in 2020, very excited,” he concluded.

CIIX is a diverse company driven not only by sales of cosmetics, hemp wine and CBD but also educational services. CIIX offers its audience of Chinese-speaking investors real-time market commentary, analysis and educational-related services in Chinese character language sets.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

• American Cancer Society annual report shows largest single-year drop in cancer deaths ever reported
• Doctors attribute precision medicine with playing significant role in decline
• POAI leading player in precision medicine, initiated groundbreaking Cancer Quest 2020 project

A new American Cancer Society report bodes well for Predictive Oncology Inc. (NASDAQ: POAI), a company focused on applying artificial intelligence to help equip players in personalized medicine and drug discovery. American Cancer Society’s annual ‘Facts & Figures 2020’ report shows the largest single-year drop in cancer deaths ever reported (http://ibn.fm/1d3lE). The 2.2% drop occurred from 2016 to 2017, the most recent year for which complete data is available.

The report notes that the decline in deaths from lung cancer drove the record drop, and that the decline was driven in large part by precision medicine. While lung cancer is still the leading cause of cancer death, deaths from lung cancer have declined by 51% from 1990 to 2017 among men and 26% from 2002 to 2017 among women. In response to the report, doctors at Roswell Park Comprehensive Cancer in Buffalo, New York, attribute precision medicine with playing a significant role in the decline (http://ibn.fm/14kPm).

Roswell Park’s Dr. Carl Morrison described the impact that precision medicine has had on the health industry’s fight against cancer. For example, there are at least 10 to 15 subtypes of lung cancers that doctors can treat now, which patients couldn’t receive treatment for previously. “Ten years ago, you stopped at that diagnosis,” Morrison said in an article. “Today you don’t. No longer can you just use the word lung cancer. You have to clarify what types of lung cancer it is, and then when you know what type of lung cancer it is, you know what specific therapy that you can treat that lung cancer with and that is in essence, precision medicine.”

As precision medicine continues to be embraced by the health community, Predictive Oncology’s database shows potential to fill a critical void: equipping oncological and pharmaceutical industries with tools to help fight ovarian cancer – a notoriously fast-moving and aggressive cancer type. Last year, POAI initiated its Cancer Quest 2020 project, which includes sequencing ovarian cancers and building the largest ovarian cancer multi-omic database in the world. Through this project, the company hopes to provide the pharmaceutical industry critical tools to help speed up the development of new drugs and provide more personalized and effective therapeutic choices.

Predictive Oncology’s subsidiary, Helomics, is playing a key role in the groundbreaking project. Helomics currently has an estimated 150,000 cases on its molecular information platform – 38,000 of which are specific to ovarian cancer. This invaluable scientific asset positions POAI as a leader in providing the critical molecular information needed for more effective patient treatments and new drug discovery in a much timelier manner than others in the precision-medicine space.

As part of the Cancer Quest 2020 project, Predictive Oncology has also signed a collaborative agreement with the University of Pittsburgh Medical Center (UPMC)-Magee Women’s Hospital to establish a data- and artificial-intelligence-driven approach to treating ovarian cancer. Based on the agreement, the partnership is designed to validate the significant value of using AI-powered decision-making for identifying specific treatments on specific genotypes to help oncologists predict clinical outcomes for ovarian cancer patients.

Helomics has begun sequencing retrospective ovarian cancer cases from the UPMC-Magee collaboration and analyzing the mutations in the tumor (genome) and the expression of genes (transcriptome) in order to build a comprehensive multi-omic picture of the tumor. That information can then be brought together with Helomics’ data set of drug-response profiles to build an AI-driven predictive model of ovarian cancer. This disruptive work is designed to lead to continued drops in cancer deaths of all types.

Predictive Oncology began as a joint venture between Skyline Medical, another of POIA’s subsidiaries, and Helomics. The company is ideally positioned to harness the power of artificial intelligence and work with the pharmaceutical, diagnostic and biotech industries to develop highly customizable assessment methods for cancer patients.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Merger with Pura Vida Health seen as mutually beneficial for both players in the CBD health and wellness space
• EMOR’s Pura Vida business plan allows the company to achieve full vertical integration
• The company promises quality control of CBD product offerings, from seed to shelf

Emerald Organic Products Inc. (OTC: EMOR), a diversified cannabidiol (CBD)-focused health sciences company, recently announced the completion of a definitive plan to merge with Pura Vida Health LLC, a health and wellness company focused on using natural ingredients – including the increasingly desired CBD – to help customers achieve optimal health. This mutually beneficial merger is expected to allow Pura Vida to become a flagship brand for Emerald Organic Products and position the former for maximum market penetration, with the help of EMOR’s proven track record in product branding and sales.

“We believe in the all-star team we put together, we have proven experts in cannabis, hemp, CBD,” Pura Vida CEO and Executive Chairman Matt Dill stated in a news release (http://ibn.fm/tfRrQ). “I am talking all phases: planting, farming, extracting, the whole way, fully vertical.” Commenting on how his company will benefit from the alignment with Emerald Organic Products, he noted, “Add a group of professionals with a track record of successful branding of products, hundreds of millions in sales, [it’s] very exciting.”

Pura Vida is focused on bringing products to market that are engineered to help people live their healthiest lives. The company is committed to providing the highest quality products using natural ingredients and third-party testing (http://ibn.fm/j5YKm). Coupling Pura Vida’s insistence on quality with EMOR’s marketing muscle is expected to lend the combined firm an advantageous position in the burgeoning industry.

Based out of New York, Emerald Organics Products plans to market its recently commercialized line of vitamins and supplements both across the nation and in certain foreign countries. Its Pura Vida business plan will allow it to achieve full vertical integration – ensuring absolute quality control, from seed to shelf. The process includes careful monitoring of hemp growth and CBD extraction and following the product through manufacturing and production at its facilities in Oregon and New York, respectively. By overseeing each stage, Emerald Organics Products will be one step closer to its goal of ‘leading the hemp revolution’ (http://ibn.fm/lWjJt).

Creating a symbiotic relationship between the two companies, the merger comes at an opportune time. According to Grand View Research, the global cannabidiol market was valued at $4.6 billion in 2018 and is forecast to experience an impressive CAGR of 22.2% through 2025 (http://ibn.fm/PS3WC). In the health and wellness industry, there is particularly high demand for products infused with CBD due to its healing properties, including its efficacy in treating anxiety, depression and stress; its mitigation of cancer symptoms; and other applications. As government legalization and approval continue to roll through North America, the potential for companies bringing CBD offerings to market is also anticipated to grow.

Emerald Organic Products Inc. is engaged in the development of vitamins and supplements with cannabidiol (CBD) health and wellness products. The hemp-based proprietary Pura Vida CBD products include CBD vitamins, chewable CBD gummies and gummy bears, vaporization CBD liquids, drinks, CBD tinctures, CBD cosmetics and others.

For more information, visit the company’s website at www.Emerald-Organic.com

• Xalles Holdings is developing its fintech network to embrace technological solutions for a new era, including anticipated needs of the cryptocurrency alt coin trading sector
• Cryptocurrency market watchers are anticipating a new round of volatility during the coming spring as the newest round of bitcoin “halving” occurs, creating opportunity for a powerful crypto trading engine to generate confidence in quick transactions
• The company is also anticipating new revenue as it delivers a new X2X software platform for reconciling financial transactions in business and government payment applications

With the dawn of a new decade now upon us, market watchers are preparing for a new round of volatility in cryptocurrencies as bitcoin, the most popular of all the alt coins established as a free-trade bankless monetary system, undergoes a new round of “halving” that cuts creation of the cryptocurrency by 50 percent. The automated halving process is expected to occur sometime in May 2020 to control inflation, and is further expected to send the cryptocurrency through sharp price increases as well as sharp drops in its value (http://ibn.fm/ndbfl).

Fintech holding company Xalles Holdings Inc. (OTC: XALL) has been positioning itself as a strong player in the crypto and blockchain realms, readying its partner’s cryptocurrency trading engine that nimbly facilitates fast and efficient cryptocurrency transactions to give traders a measure of confidence if they intend to ride out the market’s volatility.

Alt coins arose as something of a libertarian effort for people to securely network financially with one another through the blockchain’s immutable ledge system without a fiat system’s oversight, but a variety of frauds and untimely deaths have exhibited the risks inherent to such an enterprise. The ability to quickly complete trades helps value holders to mitigate some of those risks.

When Argentina’s central bank attempted to put a limit on how many U.S. dollars its citizens could buy on the currency exchange markets in October to fight inflationary trends, it drove many people to buy bitcoin instead in protest of government controls on their finances (http://ibn.fm/CE8wf).

Xalles is chiefly devoted to providing a diverse number of payment transaction consulting solutions to government entities, businesses and individual consumers. The company’s revenues are obtained through a share of the till when clients establish a financial transaction toll gate, according to an interview with the company’s CEO, Thomas Nash (http://ibn.fm/Br6XD).

Xalles’ revenue-sharing agreement with All the Numbers Trading Company, LLC (ATN Trading) to develop a cryptocurrency engine similar to the automated “bots” used by experts in the stock market is an example of its work with partners to roll out innovations. Under the agreement, Xalles will ensure the distribution of the tech solution to a large community of traders among its contacts and within its client base.

“After months of testing ATN Trading’s system, we are highly impressed with the results; it exceeded our expectations,” Nash stated when the agreement was announced in September (http://ibn.fm/aWk4H). “We selected ATN Trading as our revenue sharing partner because of the integrity of the platform and its unique pricing model. This as an excellent opportunity for us to profitably participate in the cryptocurrency investment market segment.”

Xalles is also nearing development completion of its blockchain-based solution for business and government payments and post-payment auditing. The solution, dubbed the X2X system, will facilitate financial transaction reconciliation and is expected to generate revenue when it is deployed during the coming year.

Digital technology innovator Accenture reported recently in its ‘Workforce 2025: The Financial Services Skills & Roles of the Future’ study that financial services companies in North America could gain up to $140 billion in productivity improvements and cost savings by 2025 if they adequately integrate new technologies for making their workforces more efficient (http://ibn.fm/gGl3j).

For more information, visit the company’s website at www.Xalles.com

NOTE TO INVESTORS: The latest news and updates relating to XALL are available in the company’s newsroom at http://ibn.fm/XALL

• The traditional digital media model was broken; Jerrick built a new one
• Jerrick’s proprietary Vocal platform gives content creators powerful storytelling, money-making, audience-building tools
• With over 500,000 Vocal creators and 8 million monthly visitors, Jerrick’s market penetration still in its early stages

In today’s digital world, demand for user-generated content is soaring. Every minute on the Internet, more than 4 million videos are viewed on YouTube. In that same minute, 1,440 WordPress posts are published, 481,000 tweets are sent, and 174,000 Instagram posts are viewed. These numbers are expected to only continue to rise. Jerrick Media Holdings Inc. (OTC: JMDA) empowers creators with Vocal, a platform strategically designed to drive value for the virtually infinite number of digital content creators.

Jerrick is a holding company focused on developing technology-based solutions. The company pursues a simple, straightforward mission: to provide creators with the technology and resources to get discovered and earn money to fund their creativity. The company achieves this mission through Vocal, its proprietary longform publishing platform equipped with storytelling tools and engaged communities for content creators of all kinds.

Early on, Jerrick recognized the problems associated with the traditional digital media model. The company identified systemic flaws and threats inherent in the digital media industry, including limited paths to profitability, high content creation costs, excessive traffic requirements to monetize, compressing margins on display advertising, and high marketing and general operational expenses.

“The traditional digital media model was broken,” the company notes in its corporate overview (http://ibn.fm/VfE5i). “So we built a new one.”

When Jerrick set out to build its proprietary technology – together with its development partner, Thinkmill – the focus was first and foremost on building a platform ecosystem that would generate revenues for all platform stakeholders through a sustainable and scalable business model. Jerrick’s business model is predicated on partnership with Vocal creators, and, as referenced in their corporate overview, “features numerous revenue touch-points throughout the Vocal ecosystem, ensuring a balanced portfolio of revenue streams, sustainable infrastructures, and compounding scalability.”

Further, Jerrick’s technology is optimized for scale and built to support future development, utilizing its first-party behavioral data to continually improve the experience for creators. “Vocal’s proprietary technology can seamlessly absorb a nearly endless supply of external assets, allowing for opportunities to revive distressed media content at a fraction of its original cost and with limited increase to Jerrick’s operational expenses,” the company’s corporate overview notes.

Vocal provides digital creators of every kind – from artists to writers, musicians, entrepreneurs, and more – with powerful storytelling tools and engaged genre-specific communities. Using Vocal, content creators benefit from access to a built-in engaged audience as well as monetization opportunities (from reads and tips). Vocal also touts a safe and curated environment, which is a tremendous value proposition for creators. This safety is also attractive to the brands partnering with Vocal for Brands, Jerrick’s creative studio that partners brands with creators to product authentic brand content to build affinity, trust, and drive conversions.

“Vocal is a technology platform that is of a caliber associated with only a few hundred other digital platforms,” Jerrick CEO Jeremy Frommer stated in a weekly review (http://ibn.fm/G1zOi), adding that Vocal has grown into one of the top online creator platforms. As of January 2020, approximately 400-500 creators join the platform every day, with approximately 5-10% of those upgrading to Vocal+ (http://ibn.fm/lG78z) – the company’s premium subscription membership program – within a week.

Jerrick Media Holdings is focused on the development of digital communities, targeted marketing of branded digital content and e-commerce opportunities. To accomplish these objectives, Jerrick envisions, designs and builds modern technology companies that redefine how people interact with technology. As the parent company of Vocal, Jerrick has built and shipped products that have influenced millions of people worldwide.

To view Jerrick’s 2020 Corporate Overview, visit http://ibn.fm/WxJIj

For more information, visit the company’s website at https://Jerrick.media

NOTE TO INVESTORS: The latest news and updates relating to JMDA are available in the company’s newsroom at http://ibn.fm/JMDA

• Consumers are becoming more interested in cryptocurrency and alternative methods of payment
• Recent revenue sharing partnership will allow the company to provide its customers access to ATN Trading’s a fast and efficiency crypto trading engine
• Xalles was among the first providers of payment and financial transaction management solutions through proprietary blockchain-based X2X technology

As the cryptocurrency sector is expanding and there is growing demand and interest in crypto payment solutions, fintech holding company Xalles Holdings Inc. (OTC: XALL) is intent on becoming the go-to option on the automated cryptocurrency trading market while making trading and related services more accessible to clients of any size.

A growing number of banks are developing cryptocurrency strategies as Federal Reserve interest rates plummet. Fiat money is very vulnerable to centralized bank control, which paints a good picture for a decentralized system such as Bitcoin, which are not susceptible to direct influence by bankers and governments (http://ibn.fm/Hx6xZ).

In addition, more and more consumers are interested in cryptocurrency and other alternative payment methods. About 75 percent of respondents in a Global Payments Insight Study by ACI Worldwide and Ovum said consumers want a broader choice of payment tools, prompting companies to consider investing in this area, and mobile payment systems in general are expected to grow in popularity and will become less dependent on fiat currencies, according to Business Insider Intelligence. Among the consequences of this is that non-cash transactions will surpass one trillion by 2023 (http://ibn.fm/x7Y0c).

Xalles Holdings is uniquely positioned to take advantage of these new market opportunities and emerge as a reputed provider of automated crypto trading options. The company’s recent partnership with All The Numbers Trading Company, LLC (d/b/a ATN Trading) to enhance distribution of the latter’s powerful crypto trading solution is the first major step in this direction. The agreement signed between ATN Trading and Xalles Holdings’ wholly owned subsidiary Xalles Financial Services Inc. provides that the companies will share revenue resulting from the distribution of ATN’s crypto trading engine (http://ibn.fm/Q2cj6).

Under the agreement, Xalles will distribute the crypto trading engine to a large community of traders among its contacts and within its client base of expert traders and institutional firms. Customers will be able to connect their Coinbase or Binance accounts to ATN’s automated cryptocurrency trading engine to trade a vast number of many currencies and will not be required to pay a fee if they don’t make a profit. The ATN trading system offers quick and efficient trading, thus addressing one of the largest issues with cryptocurrencies – their relatively high volatility as they are traded 24/7, making fast trading crucial for profitability and success.

The agreement is also an excellent opportunity for Xalles to profitably participate in the cryptocurrency investment market while also advancing the company’s plans to make cryptocurrency trading and other related services more accessible to clients for large and small traders.

Xalles Holdings’ business plan focuses on business, consumer, and government-oriented payment and financial reconciliation transactions. Xalles is building technology that supports payment exchange, audits, and new business models and opportunities all over the world by combining the blockchain decentralized financial ledger platform with the company’s existing, state-of-the-art transaction reconciliation system design. Xalles will launch new reward systems and services card and mobile payment and will expand the technology offerings for e-commerce engines and referral marketing.

Xalles was among the first providers of payment and financial transaction management solutions through proprietary blockchain-based X2X technology. One of these solutions is the IFS (Investment and Financing System), which provides links to Xalles’ Financial Transaction Reconciliation (FTR) solution, supports complex investment structures, assists international investment corporations, and more.

Always on the lookout for fintech growth and acquisition opportunities, Xalles Holdings aims to become the main payment system provider in strategic partner solutions. The company devises customized approaches to help companies enhance their market presence and achieve success in their financial transaction system offerings by providing various levels of investment services and funds, including blockchain and other technologies for payments, e-commerce, payment-auditing solutions and financial reconciliation.

For more information, visit the company’s website at www.Xalles.com

NOTE TO INVESTORS: The latest news and updates relating to XALL are available in the company’s newsroom at http://ibn.fm/XALL

• Growing interest in the company’s innovative DehydraTECH™ drug delivery platform from large global corporations
• Lexaria’s strategy to be listed on a nationally recognized U.S. exchange will help the company access a significantly larger audience of investors
• Lexaria has 16 patents with another 60 pending worldwide and is the only company to hold a patent for improved delivery of all non-psychoactive cannabinoids

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, has achieved virtually everything it set out to do in 2019 and has even bigger plans for 2020 that include achieving higher revenue and being listed on a major U.S. exchange, according to CEO Chris Bunka in a strategic update to shareholders (http://ibn.fm/zA8bd). While its shares remain “dramatically undervalued” at the moment, Bunka said, the company boasts a successful 2019 during which it signed different partnerships and agreements for use of its innovative DehydraTECH™ drug delivery platform.

The revolutionary drug delivery platform accelerates human intestinal cell absorption of bioactive substances administered without the need for inhalational dosing, co-administration with sugars or sweeteners, and other unhealthy practices. It is applicable to a wide variety of bioactive substances, including cannabis and nicotine. The innovative technology makes it possible to deliver bioactive substances via oral ingestion bypassing potentially unhealthy and unsafe practices. It has been shown to accelerate CBD absorption by 499 percent and achieve a CBD blood concentration 319 percent higher than traditional formulation.

The company developed its platform based on recognition of the fact that inhalation poses certain risks. Edible ingestion makes it possible to absorb a substance in a healthier and safer way. The platform has also been proven to deliver up to 10 times more of active ingredients in comparison to traditional edibles. DehydraTECH™ is the first platform of its kind that allows users to access the primary benefits of inhalation – speed and efficiency – while circumventing the risks of inhalation.

Lexaria Bioscience currently has 16 patents granted and more than 60 patent applications worldwide and is the only company to hold a patent for improved delivery of all cannabinoids and nicotine. According to Bunka, one of the company’s biggest achievements in 2019 was receiving the first ever patents to use DehydraTECH™ with cannabinoids for the treatment of Alzheimer’s, Parkinson’s, schizophrenia and heart disease, in Australia. Lexaria is working to gain fast-track patent status for the same health conditions in the U.S. this year, which will allow the company to achieve one of its goals for 2020 – developing relationships in the pharmaceutical industry, as well.

In 2019, the company also finalized a new contractual relationship with a GMP-certified, FDA registered production company to get enhanced DehydraTECH™ powders to market in the U.S. with current capacity of roughly 200,000 servings per day. According to Bunka, this can increase to 400,000 servings per day within the same facility. “Lexaria is experiencing strong demand from many companies requesting pre-processed DehydraTECH-enhanced bulk powders for their specific product lines and with this facility, we can meet that demand,” he said in a news release.

In 2020, the company expects to more than double its entire 2019 revenue from existing clients in the context of a projected sustainable revenue growth all throughout the year and beyond by leveraging a rich pipeline of prospective additional clients to be onboarded the following months, Bunka explained. “One of our existing U.S. clients is embarking on an aggressive growth strategy from their home state to several additional states within the next year. Another existing U.S. client is in the next 90 days launching their bottled beverage with CBD and DehydraTECH technology within, generating first-ever revenue for Lexaria during Q1,” Bunka continued.

This revenue increase will support the company’s own future growth plans. To increase its market visibility and ultimately expand its customer base, Lexaria Bioscience plans to dramatically alter its capital markets strategy this year to qualify for listing on a nationally recognized U.S. exchange. The company has already met with several Wall Street investment banking firms for this purpose. Listing on a major U.S. exchange would allow Lexaria Bioscience access to a significantly larger audience of investors and open a path to a growing number of more lucrative strategic opportunities, Bunka concluded.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP